Licorice extract to reduce side effects of CAR-T cell therapy
Part of Cancer, Immune system & allergy clinical trials.
This study tests whether a licorice-based supplement called diammonium glycyrrhizinate can help reduce harmful side effects while improving the effectiveness of CAR-T cell therapy—an advanced immunotherapy used to treat large B-cell lymphoma. You would take this supplement by mouth alongside your CAR-T treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old
- You have been diagnosed with large B-cell lymphoma and are scheduled to receive CAR-T cell therapy
- Your liver, kidneys, heart, and lungs are working well enough (based on blood tests and imaging)
- You do not have lymphoma that has spread to your brain or spinal cord
- If you can have children, you agree to use reliable birth control during the study
- You can understand the study and sign a consent form yourself or with a legal guardian's help
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at adding a supplement called beta-hydroxybutyrate (BHB) to standard CAR-T therapy for people with large B-cell lymphoma. It may help improve how well the treatment works.
This trial tests if the drug emapalumab can help prevent toxic side effects often caused by CAR-T cell therapy. It is for adults with certain types of large B-cell lymphoma that have not responded to or returned after initial treatment.
This trial tests combining an experimental drug (CLS-015) with a standard CAR-T cell therapy for people with large B-cell lymphoma whose disease is stable or progressing. It aims to see if the combination is safe and might improve treatment outcomes.
This trial tests a combination of two medications (golcadomide and rituximab) as a short-term treatment to shrink lymphoma before you receive CAR T-cell therapy. The goal is to make the CAR T treatment more effective for people whose lymphoma has come back or hasn't responded to previous treatments.
This trial tests a new type of immune cell therapy (CAR-T) that targets two proteins on cancer cells—CD19 and CD22—to treat lymphoma or leukemia that has come back or not responded to standard treatment. It aims to see if this two-target approach works better.
This trial tests a combination of two drugs, tafasitamab and lenalidomide, as a first follow-up treatment for people with large B-cell lymphoma that did not fully go away after CAR-T therapy. The goal is to see if this drug pair can help shrink or control the remaining cancer.
Hear when a new Patients With Large B-cell Lymphoma Receiving CAR-T Cell Therapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.